Results 211 to 220 of about 80,572 (259)
Some of the next articles are maybe not open access.
Pharmaceutical Medicine, 2014
Introduction Post-marketing activities to continuously assess new drugs have been actively driven around the world. In Japan, post-marketing surveillance (PMS) studies have commonly been performed to assess the safety and efficacy of new drugs in the clinical setting, in tandem with the safety reporting system.
Kazuhiro Kanmuri, Mamoru Narukawa
openaire +1 more source
Introduction Post-marketing activities to continuously assess new drugs have been actively driven around the world. In Japan, post-marketing surveillance (PMS) studies have commonly been performed to assess the safety and efficacy of new drugs in the clinical setting, in tandem with the safety reporting system.
Kazuhiro Kanmuri, Mamoru Narukawa
openaire +1 more source
Drug Safety, 1998
The Drug Safety Research Unit (DSRU) is the centre for prescription-event monitoring (PEM) in England. PEM studies are noninterventional observational cohort studies which monitor the safety of newly marketed drugs. The need for post-marketing surveillance is well recognised in the UK and general practice is an ideal source of data.
openaire +2 more sources
The Drug Safety Research Unit (DSRU) is the centre for prescription-event monitoring (PEM) in England. PEM studies are noninterventional observational cohort studies which monitor the safety of newly marketed drugs. The need for post-marketing surveillance is well recognised in the UK and general practice is an ideal source of data.
openaire +2 more sources
[Post-marketing surveillance studies].
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2005Approval of a drug on the market is typically considered as the successful endpoint of a long development phase. This often leads to reduced interest in further research for the indication approved, while in contrast the patient's as well as physician's interest in further research increases. This paper discusses the main areas of effectiveness, safety
I, Pigeot, J, Windeler
openaire +1 more source
Phase IV Study and Post-Marketing Surveillance of Ofloxacin in Japan
Chemotherapy, 2009Data derived from phase IV clinical trials of ofloxacin in 13,850 patients show that the incidence of adverse drug reactions was 2.6%. Gastrointestinal symptoms topped other symptoms in order of frequency, followed by neuropsychiatric and hypersensitivity symptoms.
M, Sawada +4 more
openaire +2 more sources
Post-marketing safety of panitumumab: a real-world pharmacovigilance study
Expert Opinion on Drug SafetyPanitumumab has been extensively applied in antitumor therapy, and the regulation of its adverse drug reactions (ADRs) has become extremely important. This study utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to extract real-world panitumumab ADR signals and provide relevant information for drug safety ...
Heli Wen, Yuqing Lei, Lingjie Mao
openaire +2 more sources
Naltrexone: a post-marketing surveillance study
1989Since 1985 we have been evaluating the side effects of chronically administered naltrexone in heroin addicts. To date the study includes 91 patients. The side-effects were the following: protracted abstinence, 41%, headache 29%, less appetite 27% of the patients.
Bergonzini G +3 more
openaire +1 more source
Post-pandemic marketing: when the peripheral becomes the core
Journal of Research in Interactive Marketing, 2022Jagdish N Sheth
exaly
Influencer marketing: brand control, commercial orientation and post credibility
Journal of Marketing Management, 2020FRANCISCO J Martínez-López +2 more
exaly